Analysts predict that Inovio Pharmaceuticals Inc (NASDAQ:INO) will report sales of $2.63 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Inovio Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.10 million and the highest estimate coming in at $4.15 million. Inovio Pharmaceuticals posted sales of $2.65 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 0.8%. The company is expected to issue its next quarterly earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that Inovio Pharmaceuticals will report full-year sales of $31.69 million for the current year, with estimates ranging from $28.10 million to $35.28 million. For the next financial year, analysts forecast that the company will report sales of $16.90 million per share, with estimates ranging from $4.20 million to $29.60 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.22). Inovio Pharmaceuticals had a negative net margin of 252.95% and a negative return on equity of 71.53%. The company had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $7.50 million. During the same period last year, the business earned ($0.31) earnings per share.
Several research analysts have issued reports on the stock. BidaskClub raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 18th. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 16th. ValuEngine upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, May 18th. Maxim Group reiterated a “buy” rating and issued a $8.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, May 21st. Finally, Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $11.25.
In related news, CFO Peter Kies sold 35,000 shares of the firm’s stock in a transaction dated Tuesday, July 10th. The shares were sold at an average price of $4.44, for a total value of $155,400.00. Following the completion of the sale, the chief financial officer now owns 97,088 shares in the company, valued at $431,070.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.40% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. MetLife Investment Advisors LLC acquired a new position in shares of Inovio Pharmaceuticals in the fourth quarter valued at approximately $150,000. Levin Capital Strategies L.P. raised its position in shares of Inovio Pharmaceuticals by 80.5% in the second quarter. Levin Capital Strategies L.P. now owns 37,000 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 16,500 shares during the last quarter. Emerald Advisers Inc. PA acquired a new position in shares of Inovio Pharmaceuticals in the second quarter valued at approximately $228,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Inovio Pharmaceuticals by 50.2% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 101,225 shares of the biopharmaceutical company’s stock valued at $397,000 after purchasing an additional 33,825 shares during the period. Finally, New York State Common Retirement Fund grew its holdings in Inovio Pharmaceuticals by 14.3% in the first quarter. New York State Common Retirement Fund now owns 146,243 shares of the biopharmaceutical company’s stock valued at $689,000 after purchasing an additional 18,300 shares during the period. Institutional investors own 32.56% of the company’s stock.
Inovio Pharmaceuticals stock traded up $0.10 during midday trading on Tuesday, hitting $4.46. 416,780 shares of the company’s stock were exchanged, compared to its average volume of 682,208. Inovio Pharmaceuticals has a 12-month low of $3.64 and a 12-month high of $7.00. The company has a market capitalization of $398.93 million, a P/E ratio of -4.09 and a beta of 1.67.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Read More: Trading Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.